Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions

Inclusion Criteria: * Subjects will be females or males, smokers or non-smokers * 18 years of age and older * Subjects should read, sign and date an Informed Consent Form prior to any study procedures * Subjects must complete all screening procedures within 28 days prior to the administration of the study medication Exclusion Criteria: * Breast feeding female subjects * Clinically significant anormalities found during medical screening * Any clinically significant gastrointestinal pathology or unresolved gastrointestinal symptoms susceptible of interfering with the absorption of drugs * Clinically significant illnesses within 4 weeks of the administration of study medication * Abnormal laboratory tests judged clinically significant * ECG abnormalities or vital sign abnormalities at screening * Subjects with BMI greater than or equal to 30.0 * History of allergic reactions to cabergoline or ergot derivatives * Any food allergies, intolerances, restrictions, or special diet which in the opinion of the medical subinvestigator, contraindicates the subject's participation in the study * Positive urine drug screen at screening * Positive testing for hepatitis B, hepatitis C or HIV at screening * Positive urine pregnancy test at screening (performed on all females) * Use of investigational drug or participation in an investigational study, within 30 days prior to administration of the study medication * Donation of plasma (500 mL) within 7 days or donation or significant loss of …